The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease

Expert Opinion on Drug Safety

Volumn 8, Issue 2, 2009, Pages 203-210

  Federici, Augusto B ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Efficacy and safety; Inherited von Willebrand disease; Plasma derived von Willebrand factor VIII concentrates; Von Willebrand factor

Indexed keywords

8Y; ALLOANTIBODY; BIOSTATE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; EMOCLOT; FANDHI; KOATE DVI; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR PLUS BLOOD CLOTTING FACTOR 8 CONCENTRATE; WILATE; WILFACTIN; COAGULATING AGENT;

ALLERGIC REACTION; ANAPHYLAXIS; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CHEST TIGHTNESS; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEVER; FLUSHING; GENE DELETION; HEADACHE; HEART ATRIUM FIBRILLATION; HEPATITIS B; HEPATITIS C; HOME CARE; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPERTENSION; HYPOTENSION; INFECTION; INJECTION SITE BURNING; INJECTION SITE STINGING; NAUSEA; NEOPLASM; PASTEURIZATION; PLASMA; PREGNANCY; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TACHYCARDIA; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; URTICARIA; VALVULAR HEART DISEASE; VEIN THROMBOSIS; VIRUS INACTIVATION; VOMITING; VON WILLEBRAND DISEASE; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; TREATMENT OUTCOME;

COAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FACTOR VIII; HUMANS; TREATMENT OUTCOME; VIRUS INACTIVATION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 66949168185     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330902719481     Document Type: Review

References (45)

1. Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med 2007;39(5):356-358 •• One of the most recent review articles on VWD management.
2. Sadler JE, Budde U, Eikenbgoom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006;4:2103-2114 (Pubitemid 44403432)
3. Federici AB, Castaman G, Mannucci PM for the Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002;8:607-621 •• One of the first attempts to prepare recommendations on VWD management.
4. Mannucci PM. Treatment of von Willebrand disease. N Engl J Med 2004;351:683-694 •• A critical debate on VWD therapy.
5. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 2005;16:S17-21 (Pubitemid 40756404)
6. Federici AB, Castaman G, Thompson A, et al. Von Willebrand disease: clinical management. Haemophilia 2006;12(Suppl 3):152-158 •• One of the most recent comprehensive reviews on VWD management.
7. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005;16:S23-6 (Pubitemid 40756405)
8. Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO.WILL Study. Haemophilia 2007;l5:15-24 (Pubitemid 350253400)
9. Mannucci PM. Recommended protocol for the study of the ex vivo biological effects of virus-inactivated plasma concentrates in patients with von Willebrand disease (Scientific and Standardization Committee communication). Thromb Haemost 1992;68:84-87
10. Mannucci PM, Tenconi PM, Castaman G, et al. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992;79:3130-3137
11. Mannucci PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood 1994;83:3018-3027 (Pubitemid 24142737)
12. Committee for Medicinal Products For Human Use Guideline On The Clinical Investigation Of Human Plasma Derived Von Willebrand Factor Products (CPMP/BPWG/220/02), November 2005. Available from: http://www.emea.europa.eu/ pdfs/human/bpwg/022002en.pdf
13. Mannucci PM, Chediack J, Hanna W, et al for the Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002;99:450-456 •• The first prospective clinical trial with a VWF/FVIII concentrate.
14. Federici AB, Baudo F, Caracciolo C, et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 2002;8:761-767 (Pubitemid 35446628)
15. Bello IF, Yuste VJ, Molina MQ, et al. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results.. Haemophilia 2007;13:25-32 (Pubitemid 350253401)
16. Federici AB, Barillari G, Zanon E, et al. Efficacy and safety of highly-purified, doubly virus-inactivated VWF/FVIII concentrates in patients with von Willebrand disease: an Italian retrospective study on 120 cases. Haemophilia 2009; Submitted
17. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P® in von Willebrand disease. Haemophilia 1998;4(Suppl 3):33-39 (Pubitemid 28561094)
18. Lillicrap D, Poon MC, Walker S, et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002;87:224-230
19. Franchini M, Rossetti G, Tagliaferri A, et al. Efficacy and safety of factor VIII/von Willebrand factor concentrate, Haemate-P in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003;88:1279-1283
20. Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate P in inherited von Willebrand disease: a cohort study on 100 Italian patients. Haematologica 2007;92:944-951 (Pubitemid 350144241)
21. Cox Gill J, Ewenstein BM, Thompson AR, et al. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/von Willebrand factor concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003;9:688-695 (Pubitemid 37540809)
22. Thompson AR, Cox Gill J, Ewenstein BM, et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/von Willebrand factor concentrate (Humate-P). Haemophilia 2004;10:42-51 (Pubitemid 38195624)
23. Lethagen S, Kyrle PA, Castaman G, et al. for the Haemate P Surgical Study Group. Von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007;5:1420-1430 (Pubitemid 46965370)
24. Stadler M, Gruber G, Kannicht C, et al. Characterisation of a novel high-purity, double virus inactivated von Willebrand factor and factor VIII concentrate (Wilate®). Biologicals 2006;34:281-288 (Pubitemid 44781195)
25. Favaloro EJ, Llyod J, Rowell J, et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. Thromb Haemost 2007;97:922-930 (Pubitemid 46939204)
26. Shortt J, Dunkley S, Rickard K, et al. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia 2007;13:144-148 (Pubitemid 46237945)
27. Menache D, Aronson DL, Darr F, et al. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Br J Haematol 1996;94:740-745 (Pubitemid 26308912)
28. Goudemand J, Scharrer I, Berntorp E, et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 2005;3:2219-2227 (Pubitemid 41727200)
29. Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007;5:1115-1124 (Pubitemid 46902109)
30. Shelton-Inloes BB, Chehab FF, Mannucci PM, et al. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987;79:1459-1465 (Pubitemid 17099650)
31. Mannucci PM, Tamaro G, Narchi G, et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Hematol 1987;39:467-470 (Pubitemid 18002930)
32. Bergamaschini L, Mannucci PM, Federici AB, et al. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995;125:348-355
33. Ciavarella N, Schiavoni M, Valenzano E, et al. Use of recombinant factor VIIa (Novoseven) in the treatment of two patients with type III von Willebrand disease and an inhibitor against von Willebrand factor. Haemostasis 1996;26:150-154 (Pubitemid 26076633)
34. Boyer-Neumann C, Dreyfus M, Wolf M, et al. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemost 2003;1:190-192
35. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-466 (Pubitemid 32064795)
36. Makris M, Colvin B, Gupta V, et al. Venous Thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand disease. Thromb Haemost 2002;88:387-388 (Pubitemid 35021594)
37. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002;88:378-379 (Pubitemid 35021592)
38. Kernoff PBA, Lee CA, Karayiannis P, et al. High risk of non-A non B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985;60:469-479 (Pubitemid 15032634)
39. Mannucci PM, Colombo M. Virucidal treatment of clotting factor concentrates. Lancet 1988;332:782-785 (Pubitemid 18235795)
40. UK Hemophilia Centre Directors Study group on surveillance of virus transmission by concentrates. Effects of dry-heating of coagulation factor concentrates at 80°C for 72 hours on transmission of non-A non-B hepatitis. Lancet 1988;332:814-816
41. Legler TJ, Riggert J, Simpson G, et al. Testing of individual blood donation for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection. Transfusion 2000;40:1192-1197 (Pubitemid 30782913)
42. Federici AB, Santagostino E, Rumi MG, et al. The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study. Haematologica 2006;91(4):503-508 •• The first prospective clinical study on the natural history of hepatitis C infection in VWD patients.
43. De Meyer SF, Vanhoorelbeke K, Chuah MK, et al. Phenotype correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood 2006;107:4728-4736 (Pubitemid 43882623)
44. Pasi KJ, Collins PW, Keeling DM, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004;10:218-231 •• Another attempt to prepare recommendations on VWD management. (Pubitemid 38584792)
45. Nichols WL, Hulting MB, James AH, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the national Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171-232 •• Another attempt to prepare detailed recommendations on VWD management.